A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Status: RECRUITING

Eligibility Criteria

Age:

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

* Participant has provided written informed consent and agrees to comply with the study protocol. * Participant with PBC diagnosis. * Participant for whom the treating physician has decided to start or participants who are currently receiving treatment with commercialized elafibranor. * If a participant has a caregiver who agrees to complete the caregiver questionnaires, an informed consent should be collected from the caregiver before any data is collected.

Exclusion Criteria:

* Participant is currently participating or, plans to participate in an investigational drug study or medical device study containing active substance. * Participant with known hypersensitivity to the product or to any of its excipients. * Participant with mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.

Conditions & Interventions

Conditions:
Primary Biliary Cholangitis

More Information

Contact(s): Ipsen Clinical Study Enquiries - clinical.trials@ipsen.com
Principal Investigator:
Phase:
IRB
Number:
System ID: NCT06447168
